Identification of serotonin 2A receptor as a novel HCV entry factor by a chemical biology strategy
ABSTRACT Hepatitis C virus (HCV) is a leading cause of liver disease worldwide. Although several HCV protease/polymerase inhibitors were recently approved by U.S. FDA, the combination of antivirals targeting multiple processes of HCV lifecycle would optimize anti-HCV therapy and against potential dr...
Main Authors: | Lin Cao, Jizheng Chen, Yaxin Wang, Yuting Yang, Jie Qing, Zihe Rao, Xinwen Chen, Zhiyong Lou |
---|---|
Format: | Article |
Language: | English |
Published: |
Oxford University Press
2018-03-01
|
Series: | Protein & Cell |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1007/s13238-018-0521-z |
Similar Items
-
Targeting HCV Entry For Development of Therapeutics
by: Jeffrey F. McKelvy, et al.
Published: (2010-08-01) -
Entry inhibitors: New advances in HCV treatment
by: Xi-Jing Qian, et al.
Published: (2016-01-01) -
An overview of HCV molecular biology, replication and immune responses
by: Nawaz Zafar, et al.
Published: (2011-04-01) -
Methanolic Extract of <i>Rhizoma Coptidis</i> Inhibits the Early Viral Entry Steps of Hepatitis C Virus Infection
by: Ting-Chun Hung, et al.
Published: (2018-11-01) -
Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets
by: Nathalie Alazard-Dany, et al.
Published: (2019-01-01)